GET DAILY SIGNALSAxon Enterprise (AXON) Delivers Strong Software Momentum in Q3 but Revenue Miss and Guidance Trim Send Shares Down -18.4%
Key Takeaways
- Axon Enterprise reported third quarter 2026 revenue of $908.6 million, up 28% year over year but below the roughly $935.6 million consensus estimate.
- Adjusted earnings per share (EPS) came in at $1.72, about 9% below the $1.89 consensus, while net income swung to $57 million from a prior-year loss.
- Adjusted EBITDA rose 33% to $236 million, beating the $227.9 million estimate on a 25.9% margin.
- Software & Services accelerated to 43% growth at $437 million, and annual recurring revenue (ARR) climbed 40% to $1.75 billion.
- Management trimmed full-year guidance, citing roughly $130 million of Federal counter-drone (Dedrone) deployments no longer expected in 2026.
- Shares fell sharply after the report as investors weighed softer revenue guidance against strong software momentum.
Why This Quarter Matters
Axon’s third quarter report matters because it tests whether the company’s software-first transformation can keep driving growth even as its hardware and counter-drone businesses introduce more variability. Axon has now posted several consecutive quarters of revenue growth above 30%, and its expanding recurring revenue base has anchored a premium valuation. Heading into the report, investors were watching whether Software & Services momentum, artificial intelligence adoption, and federal contract timing could offset margin pressure from hardware mix. The results delivered on the software side but revealed guidance headwinds tied to the timing of large Federal Dedrone deployments, making this quarter a key signal for how Axon’s mix of high-margin subscriptions and hardware-heavy projects will shape profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
For the third quarter ended September 30, 2026, Axon Enterprise reported total revenue of $908.6 million, a 28% year-over-year increase that nevertheless came in below the consensus estimate of roughly $935.6 million. Software & Services revenue accelerated 43% to $437 million, while Connected Devices revenue rose 16% to $472 million; within Connected Devices, Platform Solutions grew 106% to $125 million. Total gross margin declined to 56.7% from 60.1% a year earlier, while adjusted gross margin fell to 59.2% from 62.7%, reflecting a larger mix of counter-drone equipment, higher memory costs, and scaling of newer product categories.
Operating income improved to $42 million from a $2 million loss in the prior-year period. Net income reached $57 million, or $0.68 per diluted share, versus a $2 million net loss a year ago. On a non-GAAP basis, net income was $144 million, or $1.72 per diluted share, up from $1.24 in the prior year but below the $1.89 consensus. Adjusted EBITDA rose 33% to $236 million, exceeding estimates. Annual recurring revenue grew 40% to $1.75 billion, AI ARR surpassed $100 million, and net revenue retention held at 126%. From what I see, the recurring revenue trajectory continues to stand out as a core strength.
Market Reaction and Investor Sentiment
Axon shares fell sharply in the immediate aftermath of the report, dropping roughly 18.4% as investors reacted to revenue that missed consensus and fourth-quarter guidance that came in below expectations. The reaction reflected a tension between strong underlying software momentum and near-term top-line softness driven by the timing of large, hardware-heavy Federal Dedrone deployments. While adjusted EBITDA beat estimates and recurring revenue growth remained robust, the reduction in full-year guidance weighed on sentiment. The move highlighted how sensitive Axon’s premium valuation is to growth trajectory and how shifts toward hardware and counter-drone projects can create quarter-to-quarter variability that investors find harder to underwrite. I’m watching this closely as the valuation reset plays out.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will focus on whether Axon can reaccelerate revenue against a backdrop of deferred federal deployments. Management guided to fourth-quarter revenue of about $1 billion at the midpoint, below the roughly $1.07 billion consensus, and now expects full-year revenue growth of approximately 30%. The shortfall is concentrated in three large Federal Dedrone deployments representing about $130 million of revenue no longer expected in 2026, underscoring how the timing of hardware-heavy counter-drone projects can swing quarterly results.
Beyond revenue, several factors deserve attention. First, the trajectory of Software & Services growth and net revenue retention will remain central, since recurring, high-margin subscriptions support the company’s valuation. Second, gross margin trends will be important as counter-drone equipment, memory costs, and new product categories weigh on profitability. Third, Axon’s balance sheet and cash flow warrant monitoring; free cash flow was negative in the quarter partly due to a roughly $100 million strategic inventory investment, and net debt rose sequentially. Finally, watch for updates on the company’s $1.2 billion investment in drone maker Skydio and its counter-drone pipeline, which could influence both growth and margin mix in coming quarters. Investors should continue to track how federal and international deployment timing evolves, as these factors will shape the pace at which Axon converts its expanding backlog and recurring revenue base into reported results.
My Experience with Tickeron’s AI Tools
In my own research workflow, I’ve found Tickeron’s AI Screener helpful for quickly filtering stocks by technical patterns, fundamentals, and AI-driven signals. It lets me scan for breakout candidates and compare names like AXON against peers without spending hours on manual work. I typically use it to surface new ideas and confirm trends I’m already tracking before digging deeper into earnings or guidance details. It has become a practical part of how I stay on top of names with complex hardware-software mixes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AXON in upward trend: price may jump up because it broke its lower Bollinger Band on October 16, 2026
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 33 cases where AXON's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AXON's RSI Oscillator exited the oversold zone, 19 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on AXON as a result. In 57 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 28 of 37 cases over the following month. The odds of a continued upward trend are 76%.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 57 cases where AXON's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.378) is normal, around the industry mean (5.045). AXON has a moderately high P/E Ratio (171.733) as compared to the industry average of (17.993). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.058) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company
Industry AerospaceDefense
Advertisement